Impressive and durable clinical responses obtained with dabrafenib and trametinib in low-grade serous ovarian cancer harbouring a BRAF V600E mutation

Azelnidipine inhibits esophageal squamous cell carcinoma proliferation in vivo and in vitro by targeting MEK1/2

“…Trametinib is a MEK1/2 inhibitor in clinical application. 34 According to our study, azelnidipine is an inhibitor of MEK1/2. Then we compared the inhibitory effects between azelnidipine and trametinib in the PDX model.…”

Durable response to BRAF inhibitor monotherapy in recurrent metastatic low grade serous ovarian cancer

“…This outcome is in line with prior case reports of similar BRAF inhibitor efficacy in BRAF V600E mutant LGSOC. ( Tholander et al, 2020 , Lima et al, 2022 , Moujaber et al, 2018 , Combe et al, 2015 , Mendivil et al, 2018 ) These prior reports as summarized in Table 1 , describe treatment responses which are sustained, lasting well beyond the 13 month PFS recorded with MEK inhibitor monotherapy in the GOG 281/LOGS trial. Three of these six prior cases record complete responses, with majority describing responses in heavily pre-treated settings of third line or higher.…”

Borderline ovarian tumors: a review of its biology, molecular profile, and management

“…[58] Some impressive responses to this combination have been described in case reports of patients with LGOC with a BRAF V600E mutation. [59,60] In face of these results, further studies directed to this pathway, including studies for patients with BOTs, are warranted.…”